SEARCH

SEARCH BY CITATION

References

  • 1
    Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 124955.
  • 2
    Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40: 125665.
  • 3
    Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 48.
  • 4
    Kino T, Inamura N, Sakai F, et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987; 19: 369.
  • 5
    Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000; 80: 1483521.
  • 6
    Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 2001; 313: 24153.
  • 7
    Carballo M, Marquez G, Conde M, et al. Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-kappaB DNA binding. J Biol Chem 1999; 274: 93100.
  • 8
    Furuke K, Shiraishi M, Mostowski HS, Bloom ET. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway. J Immunol 1999; 162: 198893.
  • 9
    Baumgart DC, McVay LD, Carding SR. Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease. Int J Mol Med 1998; 1: 31532.
  • 10
    Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. J Am Med Assoc 2001; 285: 6437.
  • 11
    Fujisawa Healthcare Inc. Prograf® (Tacrolimus) Full Prescribing Information. In: Physician's Desk Reference. Montvale, NJ: Medical Economics Company, 2002: 1098102.
  • 12
    Jain A, Venkataramanan R, Lever J, et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. Transplant Proc 1994; 26: 160910.
  • 13
    Bueno J, Abu-Elmagd K, Mazariegos G, Madariaga J, Fung J, Reyes J. Composite liver–small bowel allografts with preservation of donor duodenum and hepatic biliary system in children. J Pediatr Surg 2000; 35: 2915.
  • 14
    Aiko S, Conner EM, Fuseler JA, Grisham MB. Effects of cyclosporine or FK506 in chronic colitis. J Pharmacol Exp Ther 1997; 280: 107584.
  • 15
    Takizawa H, Shintani N, Natsui M, et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. Digestion 1995; 56: 25964.
  • 16
    Higa A, McKnight GW, Wallace JL. Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur J Pharmacol 1993; 239: 1716.
  • 17
    Hoshino H, Goto H, Sugiyama S, Hayakawa T, Ozawa T. Effects of FK506 on an experimental model of colitis in rats. Aliment Pharmacol Ther 1995; 9: 3017.
  • 18
    Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996; 23: 32933.
  • 19
    Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92: 8769.
  • 20
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 23945.
  • 21
    Fellermann K, Rudolph B, Witthoft T, et al. Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus. Med Klin 2001; 96: 1058.
  • 22
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 23
    Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 74694.
  • 24
    Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344: 4238.
  • 25
    Fellermann K, Herrlinger KR, Witthoeft T, Homann N, Ludwig D, Stange EF. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transplant Proc 2001; 33: 22478.
  • 26
    Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 31724.
  • 27
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 3602.
  • 28
    Pascu M, Muller H-P, Muller AR, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus in a patient with toxic megacolon. Int J Colorect Dis 2003; 18: 2715.
  • 29
    Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990; 12: 401.
  • 30
    D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 13239.
  • 31
    Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 2001; 64: 2014.
  • 32
    Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 2001; 52: 299318.
  • 33
    Marsh JW, Vehe KL, White HM. Immunosuppressants. Gastroenterol Clin North Am 1992; 21: 67993.
  • 34
    Latteri M, Angeloni TG, Silveri NG, Manna R, Gasbarrini G, Navarra P. Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 47383.
  • 35
    Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 36: 6104.
  • 36
    Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 1716.
  • 37
    Kim HC, Park SB. Mycophenolate mofetil-induced ischemic colitis. Transplant Proc 2000; 32: 18967.
  • 38
    Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23: 42948.
  • 39
    Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993; 25: 11223.
  • 40
    Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 47281.
  • 41
    Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 3936.
  • 42
    Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137: 7949.
  • 43
    Matsuhashi N, Nakajima A, Watanabe K, et al. Tacrolimus in corticosteroid-resistant ulcerative colitis. J Gastroenterol 2000; 35: 63540.
  • 44
    Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus (FK506) for the treatment of perianal and enterocutaneous fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2002; 122: 670.
  • 45
    Ierardi E, Principi M, Francavilla R, et al. Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. Transplant Proc 2001; 33: 21079.
  • 46
    Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15: 3717.
  • 47
    Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30: 2002.
  • 48
    Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47: 43640.
  • 49
    Petering H, Kiehl P, Breuer C, Kapp A, Werfel T. Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506). Hautarzt 2001; 52: 4750.
  • 50
    Steffen R, Wyllie R, Kay M, Kyllonen K, Gramlich T, Petras R. Autoimmune enteropathy in a pediatric patient: partial response to tacrolimus therapy. Clin Pediatr (Phila) 1997; 36: 2959.